

## Salidroside induced repair of myocardial infarction through Nrf2/HO-1

Yanbo Fan<sup>1</sup>, Wei Wang<sup>1</sup>, Liquan Tian<sup>1</sup>, Jie Yin<sup>2\*</sup>

<sup>1</sup>Department of Cardiology, Wuhan Hospital of Traditional Chinese Medicine, Wuhan 430014, Hubei, China, <sup>2</sup>Department of Cardiology, Hubei University of Chinese Medicine, Wuhan, Hubei 430065, PR China

*Yanbo Fan and Wei Wang made same contributions*

Salidroside (SAL) has been confirmed to have some protective effects against inflammatory injury. However, little information was established as to the mechanism of these protective effects. To this effect, we designed this study to explore the protective effects and mechanisms of SAL against myocardial infarction (MI). A rat MI model was established and divided into five groups (n = 6): sham, MI, MI+SAL, MI+ LY294002 (PI3K inhibitor), and MI+SAL+ LY294002. The cardiac function and histological pathology were analyzed with a color Doppler ultrasonic diagnostic instrument. Anti-oxidative enzyme activities and the production of inflammatory media were assayed by biochemical kits and ELISA. MI size and fibrosis were assayed by Masson's trichrome staining while Bax/Bcl-2 and PI3K/Akt/Nrf2/HO-1 were assayed by Western blotting and immunofluorescence. The results showed that SAL significantly improved the left ventricle ejection fraction and fractional shortening, decreased the MI size and fibrosis, inhibited apoptosis and promoted blood vessel formation. SAL promoted anti-oxidative and anti-inflammatory abilities. Moreover, SAL enhanced PI3K/ Akt/Nrf2/HO-1 expression. To this effect, we designed this study suggested that SAL induced repair of MI via PI3K/A kt/Nrf2/HO-1.

**Keywords:** Fibrosis. HO-1. Myocardial Infarction. Salidroside. PI3K/Akt.

### INTRODUCTION

Coronary atherosclerotic disease (CAD), such as myocardial infarction (MI), is a disease characterized by myocardial cell necrosis due to the interruption of cardiac blood flow. This interruption is induced by coronary artery occlusion. The myocardial cell is a terminal differentiation cell. To this effect, myocardial injury cannot be repaired through cell regeneration. It is instead repaired through the formation of a fibrotic scar. Thus, ventricular remodeling is the main cause of cardiac insufficiency and cardiogenic death in patients with infarct. The treatment methods of current clinical applications such

as drug therapy (Thrombolysis), percutaneous coronary intervention and coronary artery bypass graft can make recanalization and myocardial revascularization progress. These, to a certain extent, reduce ventricular remodeling and improves the patient's symptoms, thereby reducing the mortality rate (Montalescot *et al.* 2013; Varenne *et al.*, 2018). However, these treatments cannot promote the regeneration of infarcted myocardium. Furthermore, the long-term prognosis of patients with MI cannot be significantly improved.

Salidroside (SAL), molecular formula C<sub>14</sub>H<sub>20</sub>O<sub>7</sub> (relative molecular mass 300.31), is a colorless transparent needle-like crystal at room temperature, which is soluble in water, ethanol, butyl alcohol and other solvents. The pharmacokinetic experiments established that SAL was mainly metabolized by the liver, excreted by the kidneys, and confers no genotoxicity to animals. Studies have

\*Correspondence: J.Yin. Department of Cardiology. Hubei University of Chinese Medicine, Wuhan. Hubei 430065, PR China. Phone: 86-02782831403. Email: fanyanbo66@outlook.com. <https://orcid.org/0000-0002-3131-5254>



is 4-Iodophenyl-3-4-nitrophenyl-5-2,4-disulfophenyl-2h-tetrazolium, monosodium salt, which reacts with a superoxide anion catalyzed by Xanthine oxidase to produce a water-soluble formazan dye. This dye can be inhibited by SOD. The absorbance at 450 nm was measured.  $H_2O_2$ , which remains after the reaction, forms a stable yellow complex with ammonium molybdate in serum or plasma under the optimal enzymatic reaction conditions. This yellow color is inversely proportional to the enzyme activity. The absorbance at 405 nm was measured for the CAT assay. According to the instructions, 20  $\mu$ l of samples, 25  $\mu$ l of Matrix buffer and 5  $\mu$ l of Coenzyme I were mixed and incubated at 37 °C for 15 minutes. Then 25  $\mu$ l of 2, 4-dinitrophenylhydrazine was added and incubated for another 15 minutes at 37 °C. Finally, 0.4 mol/L of NaOH was added for 5 minutes at room temperature and the absorbance at 450 nm was measured for LDH assay.

#### **ELISA for TNF- $\alpha$ , IL-1A and IL-6**

The total protein from myocardial tissues of the infarct area was extracted according to the instructions. The protein concentrations were determined by BCA methods. According to the kit instructions, the sample was added into the wells (100  $\mu$ l/ well) and incubated at 37°C for 90 min. After washing the plate 5 times, biotinylated antibody (100  $\mu$ l/ well) was added and incubated for 60 min at 37°C. Then after washing the plate 5 times, the enzyme conjugate working solution (100  $\mu$ l/ well) was added and incubate at 37°C for 30 min in the dark. After washing the plate 5 times, 100  $\mu$ l/ well of the chromogenic substrate was added and incubate at 37°C in dark for 15 min. After adding 100  $\mu$ l/ well of stopping solution, the OD450 value was measured immediately after mixing evenly.

#### **Masson's trichrome staining and immunostaining**

Hearts were harvested and fixed in 4% Paraformaldehyde for 24 h, cut into five transverse slices through the infarcted area. The slices were embedded in Paraffin and 5  $\mu$ M histological sections were stained with Masson's Trichrome. Infarct Size and Fibrosis

were quantified using the Image J software. The vessel density was identified by immunohistochemistry using an anti-VWF antibody. Nrf2 activation was assayed by immunofluorescence using an anti-Nrf2 polyclonal antibody and FITC-labeled secondary antibody.

#### **Western Blotting**

Myocardial tissues of the infarct area were lysed with RIPA buffer containing Protease inhibitors (Dingguo, Beijing, China). The primary antibody, Rabbit anti-Bax, Bcl-2, Nrf2, HO-1, p-PI3K and p-Akt polyclonal antibodies (1:250) were provided by Santa Cruz Biotechnology, Santa Cruz, CA. A Horse Radish Peroxidase (HRP)-conjugated anti-rabbit IgG antibody (1:5,000, Boster, Wuhan, China) was used as a secondary antibody (Li *et al.*, 2016).

#### **Statistical Analysis**


All the statistical analyses were performed with SPSS 15.0 to assess differences among the groups. The measurement data were expressed as mean  $\pm$  standard deviation. A comparison among multiple groups was performed by one-way ANOVA. The LSD *t*-test was used for comparison between the two groups. A '*p*' value less than 0.05 was considered to be statistically significant.

### **RESULTS:**

#### **SAL reduced cardiac injury**

We tested the effects of SAL on cardiac function in the rat MI model. Echocardiography was performed to evaluate the therapeutic efficacy of different treatments in the rat MI-induced heart. Heart function including ejection fraction (EF), fractional shortening (FS), and left ventricle inner diameter at systole (LVIDs) was measured 24h after reperfusion. The EF and FS in the SAL group were much higher than those in the MI group. Similarly, LVIDd in the SAL group was significantly lower compared to that of the MI group. The P13K inhibitor LY294002 could effectively reverse the effects of SAL (Figure 1A, *p* < 0.05).






**FIGURE 2** - Effects of SAL on the anti-oxidative enzyme activities in serum (A) and myocardial tissues (B) and inflammatory media (TNF-α, IL-1β, IL-6) of SAL (C). \*  $p < 0.05$  and \*\*  $p < 0.01$  vs. Sham. #  $p < 0.05$  and ##  $p < 0.01$  vs. MI; +  $p < 0.05$  vs. MI+SAL.

### SAL inhibited apoptosis and promoted vascular regeneration

MI can increase the expression of pro-apoptotic protein Bax while reducing the expression of anti-apoptotic protein Bcl-2. The expression of Bax decreased gradually while the expression of Bcl-2 increased

gradually with the administration of SAL. Furthermore, anti-VWF staining showed that the SAL group had significantly increased vessel density in the infarcted areas compared to the MI group (Figure 3B). The P13K inhibitor, LY294002 could effectively reverse the effects of SAL. This indicates that the SAL inhibited apoptosis and promoted vascular regeneration.




**FIGURE 3** - SAL inhibited apoptosis (A) and promoted vascular regeneration (B). \*  $p < 0.05$  and \*\* $p < 0.01$  vs. Sham. #  $p < 0.05$  and ##  $p < 0.01$  vs. MI; +  $p < 0.05$  vs. MI+SAL.

### SAL acted through PI3K/Akt/Nfr2/HO-1

Western blotting was performed to investigate p-PI3K, p-Akt, Nfr2, HO-1 expression in the infarcted areas following various treatments. The infarcted area in the SAL group showed a high expression of p-PI3K, p-Akt, nuclear-Nfr2 (n-Nfr2) and HO-1, which was weak

in the MI control (Figure 4A, B). Next, we determined the expression of Nrf2 in heart tissues using immunostaining. Although a small number of Nrf2 was detected in the myocardium of the MI group, more Nrf2 activation and expression were detected in the myocardium of the SAL group (Figure 4C). The PI3K inhibitor LY294002 could effectively reverse the effects of SAL.



**FIGURE 4** - p-PI3K/p-Akt/n-Nrf2/HO-1 were assayed using Western blotting (A), and Nrf2 was assayed by immunofluorescence (B). n-Nrf2 refers to nuclear Nrf2. \*\*  $p < 0.01$  vs. Sham; #  $p < 0.05$  and ##  $p < 0.01$  vs. MI; +  $p < 0.05$  and ++  $p < 0.01$  vs. MI+SAL.

## DISCUSSION

SAL has been confirmed to possess protective effects of inflammatory injury. These include cardiovascular diseases, neurodegenerative diseases, diabetes, sepsis,

and cancer (Pu *et al.*, 2020). A profound number of studies reported that SAL exhibits neuroprotective activities through the regulation of oxidative stress response, inflammation, apoptosis, and neural regeneration (Zhong *et al.*, 2018). In this study, we verified that SAL has



the regulation of apoptosis genes APAF1, DAPK1, and BCL2 in breast cancer. *Bull Exp Biol.* 2017;162(6):797-800.

Liu X, Pachori AS, Ward CA, Davis JP, Gnecci M, Kong D, et al. Heme oxygenase-1 (HO-1) inhibits postmyocardial infarct remodeling and restores ventricular function. *FASEB J.* 2006;20(2):207-16.

Lu H, Li Y, Zhang T, Liu M, Chi Y, Liu S, et al. Salidroside reduces high-glucose-induced podocyte apoptosis and oxidative stress via upregulating heme oxygenase-1 (HO-1) expression. *Med Sci Monit.* 2017;23:4067-76.

Montalescot G, Bolognese L, Dudek D, Goldstein P, Hamm C, Tanguay JF, et al. Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. *N Engl J Med.* 2013;369(11):999-1010.

Pu WL, Zhang MY, Bai RY, Sun LK, Li WH, Yu YL, et al. Anti-inflammatory effects of *Rhodiola rosea* L.: A review. *Biomed Pharmacother.* 2020;121:109552.

Sun Y, Xun L, Jin G, Shi L. Salidroside protects renal tubular epithelial cells from hypoxia/reoxygenation injury in vitro. *J Pharmacol Sci.* 2018;137(2):170-6.

Varenne O, Cook S, Sideris G, Kedev S, Cuisset T, Carrié D, et al. Drug-eluting stents in elderly patients with coronary artery disease (SENIOR): a randomised single-blind trial. *Lancet.* 2018;391(10115):41-50.

Wang J, Pan Y, Cao Y, Zhou W, Lu J. Salidroside regulates the expressions of IL-6 and defensins in LPS-activated intestinal epithelial cells through NF- $\kappa$ B/MAPK and STAT3 pathways. *Iran J Basic Med Sci.* 2019;22(1):31-7.

Wang X, Saud SM, Zhang X, Li W, Hua B. Protective effect of shaoyao decoction against colorectal cancer via the Keap1-Nrf2-ARE signaling pathway. *J Ethnopharmacol.* 2019;241:111981.

Yu Y, Yang Y, Yang M, Wang C, Xie K, Yu Y. Hydrogen gas reduces HMGB1 release in lung tissues of septic mice in an Nrf2/HO-1-dependent pathway. *Int Immunopharmacol.* 2019;69:11-8.

Zhao X, Lu Y, Tao Y, Huang Y, Wang D, Hu Y, et al. Salidroside liposome formulation enhances the activity of dendritic cells and immune responses. *Int Immunopharmacol.* 2013;17(4):1134-40.

Zhong Z, Han J, Zhang J, Xiao Q, Hu J, Chen L. Pharmacological activities, mechanisms of action, and safety of salidroside in the central nervous system. *Drug Des Devel Ther.* 2018;12:1479-89.

Received for publication on 05<sup>th</sup> May 2020

Accepted for publication on 30<sup>th</sup> July 2020